A lifestyle intervention for prostate cancer patients on ADT (V1)

  • Research type

    Research Study

  • Full title

    An exercise and nutrition intervention for locally advanced prostate cancer patients starting Androgen Deprivation Therapy

  • IRAS ID

    317895

  • Contact name

    John Saxton

  • Contact email

    john.saxton@hull.ac.uk

  • Sponsor organisation

    University of Hull

  • Duration of Study in the UK

    2 years, 1 months, 31 days

  • Research summary

    One of the common treatments for men with prostate cancer is androgen deprivation therapy (ADT). This treatment prevents androgen hormones from reaching cancer cells, slowing the cancer growth. While ADT is an effective treatment for improving cancer outcomes, it has a number of side effects.

    One of the major side effects in older men (>70 years) is a loss in muscle mass. This loss is highest in the initial months of ADT, and is important as losing muscle mass may reduce a patient’s independence and health-related quality of life. It is therefore important to research strategies to preserve muscle mass in the older prostate cancer population.

    Previous research has used exercise as a method to preserve muscle mass. While this has some benefits, older men have a smaller response to exercise than younger men. This means additional strategies are required. In this study, participants will be provided with a daily supplement containing protein and omega-3, alongside an exercise intervention. It is proposed that the addition of the supplement will help to improve muscle mass outcomes.

    This research will be conducted at Castle Hill Hospital, Hull Royal Infirmary and the University of Hull. Participants will be older men (>70 years), who have locally advanced prostate cancer, and are about to start ADT. Participants will be randomised to receive either usual care or the combined intervention. Those in the intervention group will receive 12-weeks’ worth of supplement and a guided exercise intervention, with check-ups every 4 weeks. Patients will then be followed over 6 months of follow-up, and asked to complete a final assessment after 6 months. These assessments will include physical function tests, questionnaires to assess quality of life, blood analysis, and a measurement of muscle mass using dual-energy X-ray absorptiometry (DXA).

  • REC name

    Yorkshire & The Humber - Leeds West Research Ethics Committee

  • REC reference

    23/YH/0204

  • Date of REC Opinion

    10 Oct 2023

  • REC opinion

    Further Information Favourable Opinion